Felbamate
| Clinical data | |
|---|---|
| Trade names | Felbatol |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a606011 |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | >90% |
| Metabolism | Hepatic |
| Elimination half-life | 20–23 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.042.714 |
| Chemical and physical data | |
| Formula | C11H14N2O4 |
| Molar mass | 238.243 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Felbamate sold under the brand name Felbatol, is an anticonvulsant used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox–Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia or liver failure limit the drug's usage to severe refractory epilepsy.